Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Omar Nadeem

Omar Nadeem

MD
Dana-Farber Cancer Institute

Academic History

Omar Nadeem, MD, attended Ross University School of Medicine, North Brunswick Township, NJ, where he obtained his medical degree. He then completed his internal medicine residency at the Dartmouth-Hitchcock Medical Center, Lebanon, NH, and his Hematology/Oncology fellowship at the Warren Alpert Medical School of Brown University, Providence, RI.

He is currently an Assistant Professor of Medicine at Harvard Medical School, Boston, MA, and a Senior Physician at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, Boston, MA. Dr Nadeem also serves as the Clinical Director of the Myeloma Immune Effector Cell Therapy Program and the Center for Early Detection and Interception of Blood Cancers.

Speaking on immunotherapies in multiple myeloma and related diseases

Dr Nadeem has been the principal investigator of several clinical trials across a variety of topics in multiple myeloma research. More specifically, his research is focused on monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), as well as immunotherapies, particularly CAR T-cell therapies, for patients with multiple myeloma.